| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | AMMECR1L |
| Uniprot No | Q969S7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-310aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMGKRRCVPPLEPKLAAGCCGVKKPKLS GSGTHSHGNQSTTVPGSSSGPLQNHQHVDSSSGRENVSDLTLGPGNSPIT RMNPASGALSPLPRPNGTANTTKNLVVTAEMCCYCFDVLYCHLYGFPQPR LPRFTNDPYPLFVTWKTGRDKRLRGCIGTFSAMNLHSGLREYTLTSALKD SRFPPLTREELPKLFCSVSLLTNFEDASDYLDWEVGVHGIRIEFINEKGV KRTATYLPEVAKEQDWDQIQTIDSLLRKGGFKAPITSEFRKTIKLTRYRS EKVTISYAEYIASRQHCFQNGTLHAPPLYNHYS |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是假设性的参考文献示例(请注意，AMMECR1L相关研究较为前沿，实际文献需通过学术数据库验证)：
---
1. **文献名称**: "Recombinant AMMECR1L Protein Expression and Its Role in Cellular Metabolism"
**作者**: Smith J. et al. (2022)
**摘要**: 本研究成功在HEK293细胞中表达重组AMMECR1L蛋白，证实其参与线粒体代谢通路的调控，并发现其缺失可能导致能量代谢异常。
2. **文献名称**: "Structural Characterization of AMMECR1L and Interaction with Ribosomal Proteins"
**作者**: Chen L. et al. (2021)
**摘要**: 通过X射线晶体学解析重组AMMECR1L的三维结构，揭示其与核糖体蛋白的相互作用界面，提示其在翻译调控中的潜在功能。
3. **文献名称**: "AMMECR1L Knockout Model and Recombinant Protein Rescue in Developmental Disorders"
**作者**: García-Ruiz S. et al. (2020)
**摘要**: 利用重组AMMECR1L蛋白在小鼠模型中逆转神经发育缺陷，表明其在胚胎发育中的关键作用及作为治疗靶点的潜力。
4. **文献名称**: "High-throughput Screening of AMMECR1L-binding Compounds Using Purified Recombinant Protein"
**作者**: Kim H. et al. (2023)
**摘要**: 建立重组AMMECR1L蛋白的高通量筛选平台，鉴定出小分子抑制剂，为相关癌症的靶向治疗提供先导化合物。
---
**建议**：若需真实文献，请通过PubMed或Google Scholar检索“AMMECR1L recombinant protein”或结合具体研究领域(如癌症、代谢疾病)筛选近期论文。
AMMECR1L (Alport syndrome, mental retardation, midface hypoplasia, and elliptocytosis chromosomal region gene 1-like) is a protein-coding gene located on the X chromosome (Xq22.3). The gene encodes a conserved nuclear protein implicated in RNA metabolism and transcriptional regulation, though its precise molecular mechanisms remain under investigation. AMMECR1L shares homology with AMMECR1. a gene associated with developmental disorders, suggesting potential overlapping roles in cellular processes. Studies link AMMECR1L to neurodevelopment, as mutations or dysregulation have been observed in intellectual disability syndromes and X-linked disorders.
Recombinant AMMECR1L protein is engineered to facilitate functional studies, leveraging expression systems like *E. coli* or mammalian cells to produce purified, bioactive forms. The recombinant protein typically retains key structural features, including conserved N-terminal and C-terminal domains predicted to mediate nucleic acid binding and protein-protein interactions. Researchers utilize it to explore interactions with partners like ALG-2 (apoptosis-linked gene 2) and PDCD6IP (programmed cell death 6-interacting protein), which may influence RNA processing or apoptosis pathways. Its role in modulating TGF-β signaling and cell cycle progression has also been proposed, highlighting potential relevance in cancer biology.
Clinically, AMMECR1L variants are associated with X-linked intellectual disability and cardiac abnormalities, making the recombinant protein valuable for disease modeling and therapeutic target screening. Production methods often incorporate affinity tags (e.g., His-tag) for purification and detection, followed by validation via SDS-PAGE, Western blot, or mass spectrometry. Ongoing research aims to elucidate its role in chromatin remodeling and RNA splicing, positioning AMMECR1L as a critical molecule bridging transcriptional regulation and neurodevelopmental pathologies.
×
